Day: August 12, 2025

CAMARILLO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) — via IBN – Newton Golf Company (NASDAQ: NWTG) (“Newton Golf” or the “Company”), a technology-forward golf company focused on performance-driven innovation, today announced it will host a webcast and investor Q&A session following the release of its second quarter 2025 financial results. Webcast Details Date: Thursday, August 14, 2025 Time: 4:30 PM ET Format: Webcast with Q&A Registration: https://zoom.us/webinar/register/WN_85RM9Et2RXm-e0bnl49Qjw During the webcast, Greg Campbell, Chairman and Chief Executive Officer, and Jeff Clayborne, Chief Financial Officer, will discuss the Company’s second quarter results, recent business highlights, and outlook for the remainder of 2025. The presentation will be followed by a Q&A session. The webcast is open to all shareholders,...

Q2 Revenue up 6% Year-Over-Year to $172.1 Million Q2 Net Income up 183% Year-Over-Year to $12.3 Million Q2 Gross Profit up 32% Year-Over-Year to $30.9 Million Q2 Adjusted EBITDA up 46% Year-Over-Year to $18.5 Million ATLANTA, Aug. 12, 2025 (GLOBE NEWSWIRE) — Bitcoin Depot Inc. (Nasdaq: BTM) (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM operator and leading fintech company, today reported financial results for the second quarter ended June 30, 2025. Bitcoin Depot will host a conference call and webcast at 10:00 a.m. ET today. An earnings presentation and link to the webcast will be made available at ir.bitcoindepot.com. “Bitcoin Depot delivered another strong quarter, with 6% revenue growth and a 46% increase in Adjusted EBITDA to $18.5 million,” said Brandon Mintz, Founder and CEO of Bitcoin Depot. “Our performance...

HONG KONG, Aug. 12, 2025 (GLOBE NEWSWIRE) — Century Global Commodities Corporation (“Century” or the “Company”) (TSX: CNT) is pleased to announce that it has filed its condensed consolidated interim financial statements for the first fiscal quarter ended June 30, 2025 and the related management discussion and analysis (“MD&A”). Copies of these documents are available under Century’s SEDAR+ profile at http://www.sedarplus.ca and will also be posted on Century’s website at www.centuryglobal.ca. As of June 30, 2025, the Company had unrestricted free cash, bank deposits and marketable securities totaling $3.0 million (March 31, 2025: $4.2 million) and a net working capital* of $5.7 million (March 31, 2025: $6.0 million), which is adequate to cover near-term ongoing administrative and basic mineral properties development expenses....

Management to host conference call and webcast Tuesday, August 12, 2025 at 8:30 AM ET Company continued to grow Nanox.ARC installed base and is on track to meet its year-end system deployment target PETAH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the second quarter ended June 30, 2025 and provided a business update. Recent Highlights:Generated $3.0 million in revenue in the second quarter of 2025, compared to $2.7 million in the second quarter of 2024. Grew Nanox.ARC system sales funnel exponentially in the quarter. The Company notified the FDA of its intent to submit the TAP2D software module to the FDA through the 510(k) program – a 2D view image output for the Nanox.ARC systems,...

Secured over $111 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by over $71 million in committed capital from Medtronic and Ligand Achieved multiple FDA regulatory milestones: Breakthrough Device Designation for AVIM therapy; approval for expanded BACKBEAT study enrollment criteria, and IDE approval for a U.S. pivotal Virtue SAB trial versus commercially available paclitaxel-coated balloonNEW HOPE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the second quarter ended June 30, 2025, and provided a business...

Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipated to begin in Q4 2025 High dose and low dose TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in the 12 patients treated in Part A of REVEAL Phase 1/2 trials as of August 2025 data cutoff Part A data from REVEAL Phase 1/2 trials presented at IRSF Scientific Meeting showed 100% response rate for pivotal trial primary endpoint of gain/regain of ≥ one developmental milestone, corroborated by improvements in key secondary endpoints post-TSHA-102 Company anticipates reporting new supplemental REVEAL Part A clinical data supporting TSHA-102 therapeutic impact in Q4 2025 Gross...

Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August FDA meeting scheduled in August and is intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting Publication of non-clinical data in Frontiers in Pharmacology suggests potential applications of BXCL501 in chronic conditions BioXcel Therapeutics strengthens cash position NEW HAVEN, Conn., Aug. 12, 2025 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the second quarter of 2025 and announced that its SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated...

Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating alternate dose regimens in HPV-negative patients expected by Q1 2026 Strong financial position with approximately $437 million in cash and cash equivalents as of June 30, 2025 expected to fund operations into the first half of 2029 BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the second quarter ended June 30, 2025 and provided a business update. “We continue to make excellent progress with the development of ficerafusp alfa,”...